RxDoctor Payments DataLook up a doctor →

Benjamin Bregman, MD

Critical Care Medicine · Winston Salem, NCNPI 1780863332

Payments from drug & device makers

$2,078,236in general payments, 2019–2025

Across 1,283 payments — averaging $1619.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$766K
  • United Therapeutics Corporation$430K
  • GSK$408K
  • Hoffmann-la Roche Limited$234K
  • Insmed, Inc.$101K
  • Mylan Specialty L.p.$100K
  • plus $39K from 43 others
$1,328in research payments, 2019–2025

Across 9 payments — averaging $147.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$1K

What the payments were for

  • Travel & lodging$1,67115%
  • Food & beverage$5,19748%
  • Education$4,03037%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,078,236 in reported general payments places this provider in the 95th percentile of 190 critical care medicine providers in North Carolina.

See all critical care medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$104,057
Medicare patients
370
Services billed
1,399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter89$74,365
Breztri AerosphereBudesonide/Glycopyr/Formoterol103$73,110
Stiolto RespimatTiotropium Br/Olodaterol Hcl57$30,740
Spiriva RespimatTiotropium Bromide25$15,476
Breo ElliptaFluticasone/Vilanterol32$14,013
SymbicortBudesonide/Formoterol Fumarate37$10,272
EliquisApixaban16$9,584
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$4,304
Varenicline Tartrate14$2,948
Albuterol Sulfate HfaAlbuterol Sulfate66$1,807
Ventolin HfaAlbuterol Sulfate18$1,081
Azithromycin42$367
Prednisone100$330
Fluticasone Propionate17$295
Montelukast Sodium29$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$407,941$88,378121 claims
AstraZenecaBreztri Aerosphere, Symbicort$537$83,381140 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$592$46,21682 claims
PfizerEliquis$36$9,58416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 190 critical care medicine providers in North Carolina.

Other critical care medicine in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →